Financial reports
ARS
2023 FY
Annual report to shareholders
9 Apr 24
10-K
2023 FY
Annual report
22 Feb 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
ARS
2022 FY
Annual report to shareholders
5 Apr 23
10-K
2022 FY
Annual report
23 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
15 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
Current reports
8-K
Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates
22 Feb 24
8-K
Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update
8 Jan 24
8-K
Athira Pharma Reports Third Quarter 2023 Financial Results and Pipeline and Business Updates
9 Nov 23
8-K
Athira Pharma Reports Second Quarter 2023 Financial Results and Pipeline and Business Updates
10 Aug 23
8-K
Athira Pharma Appoints Andrew Gengos as Chief Financial Officer and Chief Business Officer
22 May 23
8-K
Athira Pharma Reports First Quarter 2023 Financial Results
11 May 23
8-K
Athira Pharma Reports Full Year 2022 Financial Results and Recent Pipeline and Business Updates
23 Mar 23
8-K
Entry into a Material Definitive Agreement
6 Jan 23
8-K
Amendments to Articles of Incorporation or Bylaws
18 Nov 22
8-K
Athira Pharma Reports Third Quarter 2022 Financial Results and Recent Clinical and Corporate Updates
10 Nov 22
Registration and prospectus
S-8
Registration of securities for employees
22 Feb 24
S-8
Registration of securities for employees
23 Mar 23
424B5
Prospectus supplement for primary offering
6 Jan 23
S-8
Registration of securities for employees
28 Mar 22
S-3
Shelf registration
15 Nov 21
S-8
Registration of securities for employees
26 Mar 21
424B4
Prospectus supplement with pricing info
21 Jan 21
S-1
IPO registration
19 Jan 21
DRS
Draft registration statement
6 Jan 21
S-8
Registration of securities for employees
18 Sep 20
Proxies
DEFA14A
Additional proxy soliciting materials
9 Apr 24
DEF 14A
Definitive proxy
9 Apr 24
PRE 14A
Preliminary proxy
28 Mar 24
DEFA14A
Additional proxy soliciting materials
5 Apr 23
DEF 14A
Definitive proxy
5 Apr 23
DEFA14A
Additional proxy soliciting materials
17 May 22
DEFA14A
Additional proxy soliciting materials
16 May 22
DFAN14A
Additional proxy materials by non-management
16 May 22
DFAN14A
Additional proxy materials by non-management
12 May 22
DEFA14A
Additional proxy soliciting materials
11 May 22
Other
UPLOAD
Letter from SEC
6 Apr 22
CORRESP
Correspondence with SEC
25 Mar 22
EFFECT
Notice of effectiveness
26 Nov 21
CORRESP
Correspondence with SEC
22 Nov 21
UPLOAD
Letter from SEC
22 Nov 21
EFFECT
Notice of effectiveness
21 Jan 21
CORRESP
Correspondence with SEC
15 Jan 21
CORRESP
Correspondence with SEC
15 Jan 21
UPLOAD
Letter from SEC
6 Jan 21
EFFECT
Notice of effectiveness
18 Sep 20
Ownership